D.E. Shaw & Co
ORIC icon

D.E. Shaw & Co’s Oric Pharmaceuticals ORIC Stock Holding History

D.E. Shaw & Co’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1M Buy
1,580,216
+1,535,826
+3,460% +$13.9M 0.01% 1405
2026
Q1 		$562K Buy
44,390
+28,368
+177% +$322K ﹤0.01% 3788
2025
Q4 		$131K Buy
+16,022
New +$184K ﹤0.01% 4381
2024
Q1 		– Sell
-98,433
Closed -$906K – 4623
2023
Q4 		$906K Sell
98,433
-209,046
-68% -$1.51M ﹤0.01% 3200
2023
Q3 		$1.86M Sell
307,479
-145,770
-32% -$1.19M ﹤0.01% 2631
2023
Q2 		$3.52M Sell
453,249
-125,054
-22% -$710K ﹤0.01% 2146
2023
Q1 		$3.3M Sell
578,303
-24,484
-4% -$128K ﹤0.01% 2304
2022
Q4 		$3.55M Buy
602,787
+68,899
+13% +$233K ﹤0.01% 2412
2022
Q3 		$1.71M Buy
533,888
+27,901
+6% +$112K ﹤0.01% 3137
2022
Q2 		$2.27M Buy
505,987
+261,088
+107% +$1.04M ﹤0.01% 2957
2022
Q1 		$1.31M Buy
+244,899
New +$2.21M ﹤0.01% 3689
2021
Q2 		– Sell
-9,812
Closed -$240K – 4942
2021
Q1 		$240K Buy
+9,812
New +$310K ﹤0.01% 3790

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co's ORIC Position: Q2 2026 in Review

D.E. Shaw & Co increased its Oric Pharmaceuticals (ORIC) stake by 3,460% in Q2 2026, buying an estimated $13.9M and bringing the position to 1,580,216 shares worth $17.1M. The position accounts for 0.01% of the portfolio, ranked #1405.

D.E. Shaw & Co first reported a position in ORIC in Q1 2021 and has held it in 12 quarters since. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • D.E. Shaw & Co held 1,580,216 shares of Oric Pharmaceuticals worth $17.1M as of Q2 2026.
  • D.E. Shaw & Co bought 1,535,826 Oric Pharmaceuticals shares in Q2 2026, an estimated $13.9M.
  • Oric Pharmaceuticals made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1405 holding.
  • D.E. Shaw & Co first reported a position in Oric Pharmaceuticals in Q1 2021 and has held it in 12 quarters since.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.